Category: united states

1st retraction for researcher who lost whistleblower lawsuit

microvascular-research

A researcher who was dismissed from Wayne State University — then lost a whistleblower lawsuit against it — has logged his first retraction.

In 2012, after Christian Kreipke was dismissed from Wayne State, he filed a lawsuit, alleging that the institution had defrauded the U.S. government of $169 million in research funding. A judge dismissed the case in 2014, noting Kreipke cited “no specific facts,” and as a public university, Wayne State had immunity as an “arm of the state.”

The university’s president has said Kreipke was fired due to misconduct — not his whistleblowing, according to Courthouse News Service. 

Now, a retraction has appeared for Kreipke in Microvascular Research, citing discrepancies between the original data and what was reported in the paper. 

Here’s the retraction notice: Continue reading 1st retraction for researcher who lost whistleblower lawsuit

Cell Press won’t retract papers despite one author confessing to fraud

Screen Shot 2016-08-03 at 18.54.35Cell Press journals will not be retracting two papers that were flagged with expressions of concern (EOCs) in April after one author claimed to have manipulated some experiments.

In a strange turn of events, as we previously reported, the study’s corresponding author refuted the claims of the author who confessed to fraud, citing concerns about his “motives and credibility.” Since then, two independent labs repeated the authors’ experiments, and “largely confirm” the central conclusions of a Cell paper, but were inconclusive regarding a paper in Molecular Cell. Regardless, in both cases, the journals have decided to take no further action. 

Both expressions of concern (and their associated editorial notes) will remain online, as part of the “permanent record,” a Cell Press spokesperson told us.

The spokesperson added more about the investigation process: Continue reading Cell Press won’t retract papers despite one author confessing to fraud

Reviewers may rate papers differently when blinded to authors’ identities, new study says

Kanu Okike
Kanu Okike

Although previous research has suggested peer reviewers are not influenced by knowing the authors’ identity and affiliation, a new Research Letter published today in JAMA suggests otherwise. In “Single-blind vs Double-blind Peer Review in the Setting of Author Prestige,” Kanu Okike at Kaiser Moanalua Medical Center in Hawaii and his colleagues created a fake manuscript submitted to Clinical Orthopaedics and Related Research (CORR), which described a prospective study about communication and safety during surgery, and included five “subtle errors.” Sixty-two experts reviewed the paper under the typical “single-blind” system, where they are told the authors’ identities and affiliations, but remain anonymous to the authors. Fifty-seven reviewers vetted the same paper under the “double-blind” system, in which they did not know who co-authored the research. We spoke with Okike about some of his unexpected results.

Retraction Watch: You found that reviewers were more likely to accept papers when they could see they were written by well-known scientists at prestigious institutions. But the difference was relatively small. Did anything about this surprise you? Continue reading Reviewers may rate papers differently when blinded to authors’ identities, new study says

Yes, “power pose” study is flawed, but shouldn’t be retracted, says one author

psychological-scienceAfter the first author of a debated study about the benefits of positioning your body in an assertive ways — the so-called “power pose” — posted her concerns about the research, she has told us she does not believe the paper should be retracted.

As reported by New York magazine, late last night, the first author of a 2010 paper in Psychological Science posted a statement saying she no longer believes the effects of the “power pose” are real.

We contacted Dana Carney, now based at the University of California, Berkeley, to ask if she thought the next step would be to retract the paper. She told us: Continue reading Yes, “power pose” study is flawed, but shouldn’t be retracted, says one author

Error in one line of code sinks cancer study

journl-of-clinical-oncologyAuthors of a 2016 cancer paper have retracted it after finding an error in one line of code in the program used to calculate some of the results.

Sarah Darby, last author of the now-retracted paper from the University of Oxford, UK, told Retraction Watch that the mistake was made by a doctoral student. When the error was realized, Darby said, she contacted the Journal of Clinical Oncology (JCO), explained the issue, and asked whether they would prefer a retraction or a correction. JCO wanted a retraction, and she complied.

The journal allowed the authors to publish a correspondence article outlining their new results.

Here’s the lengthy retraction notice, published online last month: Continue reading Error in one line of code sinks cancer study

BMJ won’t retract controversial dietary guidelines article, says author

bmjThe BMJ is not going to retract a 2015 article criticizing the expert report underlying the U.S. dietary guidelines, despite heavy backlash from readers, according to the author of the article.

As Politico reported today, the publication told journalist Nina Teicholz it wouldn’t retract the article, first published one year ago today.

Teicholz confirmed to us the journal emailed her in April to say the article would not be retracted: Continue reading BMJ won’t retract controversial dietary guidelines article, says author

Amid controversial Sarepta approval decision, FDA head calls for key study retraction

FDAThe head of the U.S. Food and Drug Administration (FDA) has called for the retraction of a study about a drug that the agency itself approved earlier this week, despite senior staff opposing the approval.

On September 19, the FDA okayed eteplirsen to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in muscle degeneration and premature death. Several of its top officials disagreed with the drug’s approval, questioning how beneficial it will be for patients, as Forbes, MedPage Today and others reported.

In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients. Califf writes in the report:

Continue reading Amid controversial Sarepta approval decision, FDA head calls for key study retraction

What if scientists funded each other?

Johan Bollen
Johan Bollen

We were struck recently by a paper in Scientometrics that proposed a unique way to fund scientists: Distribute money equally, but require that each scientist donate a portion to others – turning the federal funding system into a crowd-sourcing venture that funds people instead of projects. The proposal could save the inordinate amount of time scientists currently spend writing (and re-writing) grants, but would it actually work? First author Johan Bollen, of Indiana University, explains.

Retraction Watch: You propose something quite unique: Fund everyone equally, but ask them to give a fraction of their funding to someone else. Is the idea that scientists most respected by their peers will “earn” a higher percentage of funding, and everyone is just acting as reviewers? Continue reading What if scientists funded each other?

Journal to retract study declaring safety of asbestos roofs: Report

joehOnly a few months after publication, an environmental journal has told an activist group it plans to retract a paper about the safety of roofing products containing asbestos after facing heavy criticism.

This summer, Journal of Occupational and Environmental Hygiene (JOEH) received multiple letters asking the to retract the paper. Critics of the paper — which concluded that exposures to asbestos-containing roofing products were within safety limits — argued the article provided misleading information, grouped different materials with different asbestos exposures together, and failed to note the approving editor’s ties to the asbestos industry.

The article was published as a case study, which is considered a type of “column” by the journal, thereby bypassing its peer-review system; according to an email the journal sent to the organization Right on Canada (which a representative forwarded to Retraction Watch), this served as the basis for the journal’s decision to pull the paper.

According to the email, the journal’s editorial board decided on August 10 to retract “Airborne asbestos exposures associated with the installation and removal of roofing products” due to

Continue reading Journal to retract study declaring safety of asbestos roofs: Report

Authors retract 2016 cancer study when data don’t align with figures

cell-death-and-differentiationResearchers have retracted a 2016 cancer study, citing discrepancies between the data and images presented in the paper. 

Although the retraction notice itself contains relatively little information, we’ve obtained a letter from the last author — Jun-Li Luo of The Scripps Research Institute in Jupiter, Florida — to the editor-in-chief of Cell Death and Differentiation that says a bit more. 

According to the letter, after receiving the anonymous email, Luo conducted an investigation, contacting co-authors who contributed each of the figures in question. Although Luo writes that he has no reason to suspect fraud, the researchers were not able to provide some of the original data.

PubPeer commenters have questioned figures 1, 3, 4, 5, 6 and 7 in the study, “IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy.”

In the letter, Luo tells Gerry Melino, co-editor-in-chief of the journal from the University of Leicester, UK, that figures 3D and 3E were provided by the study’s first author, Xing Fang, adding: Continue reading Authors retract 2016 cancer study when data don’t align with figures